The American Journal of Medicine
Volume 119, Issue 12, Supplement 1 , Pages S3-S10 , December 2006

Congestion in Acute Heart Failure Syndromes: An Essential Target of Evaluation and Treatment

  • Mihai Gheorghiade, MD

      Affiliations

    • Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
    • Corresponding Author InformationRequests for reprints should be addressed to Mihai Gheorghiade, MD, Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611.
    • ,
  • Gerasimos Filippatos, MD

      Affiliations

    • Department of Cardiology, Heart Failure Unit, Athens University Hospital, Attikon, Greece
    • ,
  • Leonardo De Luca, MD

      Affiliations

    • Laboratory of Interventional Cardiology, Division of Cardiology, European Hospital, Rome, Italy
    • ,
  • John Burnett, MD

      Affiliations

    • Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA

References 

  1. Gheorghiade M, De Luca L, Fonarow GC, Filippatos G, Metra M, Francis GS. Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol. 2005;96(suppl):11G–17G
  2. Gheorghiade M, Zannad F, Sopko G, et al. International Working Group on Acute Heart Failure Syndromes Acute heart failure syndromes: current state and framework for future research. Circulation. 2005;112:3958–3968
  3. ADHERE™ Scientific Advisory CommitteeFonarow GC. The Acute Decompensated Heart Failure National Registry (ADHERE™): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med. 2003;4(suppl 7):S21–S30
  4. Publication Committee for the VMAC [Vasodilatation in the Management of Acute CHF] Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287:1531–1540
  5. Kozak LJ, Owings MF, Hall MJ National Center for Health Statistics. National Hospital Discharge Survey: 2002 annual summary with detailed diagnosis and procedure data. Vital Health Stat 13. 2005;158:1–199
  6. Thom T, Haase N, Rosamond W, et al. Heart Disease and Stroke Statistics—2006 Update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113:e85–e151[published correction appears in Circulation. 2006;113:e696]
  7. Haldeman GA, Croft JB, Giles WH, Rashidee A. Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995. Am Heart J. 1999;137:352–360
  8. Cleland JG, Swedberg K, Follath F, et al. The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe (Part 1: patient characteristics and diagnosis). Eur Heart J. 2003;24:442–463
  9. Cuffe MS, Califf RM, Adams KFJ, et al. Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287:1541–1547
  10. Gattis WA, O’Connor CM. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure. Am J Cardiol. 2004;93(suppl):74B–76B
  11. Gheorghiade M, Gattis WA, O’Connor CM, et al. Acute and Chronic Therapeutic Impact of a Vasopression Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004;291:1963–1971
  12. O’Connell JB. The economic burden of heart failure. Clin Cardiol. 2000;23(suppl III):III-6–III-10
  13. Adams KF, Fonarow GC, Emerman CL, et al. ADHERE Scientific Advisory Committee and Investigators Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Failure National Registry (ADHERE). Am Heart J. 2005;149:209–216
  14. Fonarow GC, Abraham WT, Albert NM, et al. Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. Am Heart J. 2004;148:43–51
  15. Tavazzi L, Maggioni AP, Lucci D, et al. Nationwide survey on acute heart failure in cardiology ward services in Italy. Eur Heart J. 2006;27:1207–1215
  16. Nohria A, Tsang SW, Fang JC, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol. 2003;41:1797–1804
  17. Mahdyoon H, Klein R, Eyler W, Lakier JB, Chakko SC, Gheorghiade M. Radiographic pulmonary congestion in end-stage congestive heart failure. Am J Cardiol. 1989;63:625–627
  18. Adamson PB, Magalski A, Braunschweig F, et al. Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system. J Am Coll Cardiol. 2003;41:565–571
  19. Stevenson LW, Perloff JK. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA. 1989;261:884–888
  20. Lucas C, Johnson W, Hamilton MA, et al. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J. 2000;140:840–847
  21. Drazner MH, Rame JE, Stevenson LW, Dries DL. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. N Engl J Med. 2001;345:574–581
  22. Fonarow GC, Stevenson LW, Steimle AE, et al. Persistently high left ventricular filling pressures predict mortality despite angiotensin converting enzyme inhibition in advanced heart failure. Circulation. 1994;90(pt 2):I-488;Abstract 2624
  23. Binanay C, Califf RM, Hasselblad V, et al. ESCAPE Investigators and ESCAPE Study Coordinators Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA. 2005;294:1625–1633
  24. Michalsen A, Konig G, Thimme W. Preventable causative factors leading to hospital admission with decompensated heart failure. Heart. 1998;80:437–441
  25. Jain P, Massie BM, Gattis WA, Klein L, Gheorghiade M. Current medical treatment for the exacerbation of chronic heart failure resulting in hospitalization. Am Heart J. 2003;145:S3–S17
  26. Remes J, Miettinen H, Reunanen A, Pyörälä K. Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J. 1991;12:315–321
  27. Marcus GM, Gerber IL, McKeown BH, et al. Association between phonocardiographic third and fourth heart sounds and objective measures of left ventricular function. JAMA. 2005;293:2238–2244
  28. Felker GM, Cuculich PS, Gheorghiade M. The Valsalva maneuver: a bedside “biomarker” for heart failure. Am J Med. 2006;119:117–122
  29. Chakko S, Woska D, Martinez H, et al. Clinical, radiographic, and hemodynamic correlations in chronic congestive heart failure: conflicting results may lead to inappropriate care. Am J Med. 1991;90:353–359
  30. Capomolla S, Ceresa M, Pinna G, et al. Echo-Doppler and clinical evaluations to define hemodynamic profile in patients with chronic heart failure: accuracy and influence on therapeutic management. Eur J Heart Fail. 2005;7:624–630
  31. Logeart D, Thabut G, Jourdain P, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol. 2004;43:635–641
  32. Maisel AS, Krishnaswamy P, Nowak RM, et al. Breathing Not Properly Multinational Study Investigators Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161–167
  33. Gegenhuber A, Mueller T, Dieplinger B, Lenz K, Poelz W, Haltmayer M. Plasma B-type natriuretic peptide in patients with pleural effusions: preliminary observations. Chest. 2005;128:1003–1009
  34. Wu AHB, Smith A, Apple FS. Optimum blood collection intervals for B-type natriuretic peptide testing in patients with heart failure. Am J Cardiol. 2004;93:1562–1563
  35. Wu AHB, Smith A, Wieczorek S, et al. Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol. 2003;92:628–631
  36. Yu C-M, Wang L, Chau E, et al. Intrathoracic impedance monitoring in patients with heart failure: correlation with fluid status and feasibility of early warning preceding hospitalization. Circulation. 2005;112:841–848
  37. Henry JP, Gauer OH, Sieker HO. The effect of moderate changes in blood volume on left and right atrial pressures. Circ Res. 1956;4:91–94
  38. Linden RJ. Atrial receptors and heart volumes. Adv Exp Med Biol. 1995;381:125–134
  39. Mulrow PJ, Takagi M, Takagi M, Atarashi K, Franco-Saenz R. Inhibition of aldosterone secretion by atrial natriuretic peptide. Ann N Y Acad Sci. 1987;512:438–448
  40. Zucker IH, Gorman AJ, Cornish KG, Lang M. Imparied atrial receptor modulation or renal nerve activity in dogs with chronic volume overload. Cardiovasc Res. 1985;19:411–418
  41. Zucker IH, Share L, Gilmore JP. Renal effects of left atrial distension in dogs with chronic congestive heart failure. Am J Physiol. 1979;236:H554–H560
  42. Shah MR, Hasselblad V, Stinnett SS, et al. Hemodynamic profiles of advanced heart failure: association with clinical characteristics and long-term outcomes. J Card Fail. 2001;7:105–113
  43. Shah MR, Hasselblad V, Stinnett SS, et al. Dissociation between hemodynamic changes and symptom improvement in patients with advanced congestive heart failure. Eur J Heart Fail. 2002;4:297–304
  44. Fonarow GC, Hamilton MA, Moriguchi J, Creaser JW, Rourke DA. Hemodynamic predictors of clinical outcome in decompensated advanced heart failure. J Card Fail. 2001;3(suppl 2):13;Abstract 038
  45. Abraham WT, Lowes BD, Ferguson DA, et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail. 1998;4:37–44
  46. Johnson W, Omland T, Hall C, et al. Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J Am Coll Cardiol. 2002;39:1623–1629
  47. Pfeffer MA, Lamas GA. Ventricular remodeling following myocardial infarction: experimental and clinical benefits of ACE inhibition. In:  Lindpaintner K,  Ganten D editor. The Cardiac Renin-Angiotensin System. Armonk, NY: Futura Publishing Company, Inc; 1994;p. 345–358
  48. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation. 2000;101:2981–2988
  49. Paradis P, Dali-Youcef N, Paradis FW, Thibault G, Nemer M. Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc Natl Acad Sci U S A. 2000;97:931–936
  50. Cotter G, Moshkovitz Y, Milovanov O, et al. Acute heart failure: a novel approach to its pathogenesis and treatment. Eur J Heart Fail. 2002;4:227–234

PII: S0002-9343(06)01141-7

doi: 10.1016/j.amjmed.2006.09.011

The American Journal of Medicine
Volume 119, Issue 12, Supplement 1 , Pages S3-S10 , December 2006

Article Tools

* Image Usage & Resolution